ArticleMultiple sclerosis journal - experimental, translational and clinical
Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.Annals of neurology · 2026Trial
- Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.Neurology and therapy · 2026Review
- Real World Data of Laboratory Changes and Immunophenotyping in Patients with Multiple Sclerosis Treated with Ofatumumab-Single Center Experience.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives and aims: Ocrelizumab (OCR) is disease-modifying therapy that depletes B cells for the treatment of patients with relapsing and progressive multiple sclerosis (MS). The aim of this study was to evaluate occurrence of hypogammaglobulinemia and infection rates in patients with MS treated with OCR for up to 5.9 years in a real-world, single-center study. Methods: We assessed immunoglobulins IgG, IgM, IgA; CD19, CD4, CD8 cell counts, anti-JCV antibodies, at baseline and every six months prior to each OCR infusion. Mixed effects regression models controlling for random patient intercept were used to analyze immunological trends. Infections requiring oral or intravenous antibiotics were also recorded and analyzed. Results: A total of 238 patients were followed for up to 5.9 years and received a mean of 7.6 (range, 2-13) OCR infusions. IgG declined on average by 3.7% ( Conclusions: Continuous OCR treatment results in increasing hypogammaglobulinemia associated with increasing risk of moderate and severe infections. The clinical significance of these immunological findings and the influences of demographic characteristics highlight the importance of regular, personalized immunoglobulin monitoring during long-term OCR therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.